SSA
Sergio Szyldergemajn Altman
Chief Medical Officer & Founder
MD · Medical Oncologist
MSc Immuno-Oncology · Paris Sud
MSc Clinical Research · Paris VI
ESMO Certified
Therapeutic expertise
Haematological malignancies
Solid tumours
NSCLCSCLCGI tumoursGynaecologicalHRPCSTSHNSCCOthers
Modalities
ImmunotherapyTargeted therapyRLTCell therapyADCsBispecifics / T-cell engagersNanoparticles
Languages
🇦🇷 Spanish
🇬🇧 English
🇫🇷 French
View LinkedIn Profile →
Sergio is a medical oncologist with over 20 years in oncology clinical development. He helps sponsors
making the critical right clinical decisions — dose, population, endpoints, go/no-go — data-driven in its full mechanistic, pharmacological, biological and clinical context. From first-in-human
to pivotal Phase III, the focus is on turning clinical science into data-driven decisions that resonates with regulators,
investors and, above all, with patients.
He began his career caring for cancer patients in Buenos Aires and trained further in Paris, in public and private hospitals whereas post-graduate studies in clinical pharmacology, oncology and immuno-oncology, brought him overseas with
research periods in Japan and Germany. He moved early into clinical development at a European oncology
CRO, mentored by Prof. Esteban Cvitkovic, and learned to flag early data inconsistencies critically so to
anticipate the questions a sponsor sometimes overlooks. Over the following two decades he held senior
headquarters-level medical and clinical development leadership roles at European pharma and biotech
companies, across solid tumours and haematological malignancies and modalities from immunotherapy and
targeted therapy to radioligands, nanoparticles and cell therapy — shaping regulatory strategy with FDA
and EMA that effectively supported assets moving from First-in-Human to PoC and into accelerated approval or out-licensing deals and co-development.
Sergio founded DLPHI Oncology Global Consultants SARL in 2025
to support early-stage biotechs with genuinely
interesting science and expertise, but lacking partially the clinical development experience to identify roadblocks early and build a credible medical strategy, one that translates into an executable plan with regulatory milestones and secures the funding needed to deliver.
DLPHI exists to close this gap —
pragmatically, without unnecessary complexity, and always with the patient at the centre.
A full curriculum vitae is available on request.
"To get the right answers, we need first to ask the right questions."
